Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for the long term. In a report released on August 13, Seamus Fernandez from Guggenheim maintained a Buy rating on Eli Lilly and ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...

The deal allows Eli Lilly and Company (NYSE:LLY) to have exclusive rights to develop and commercialize drug candidates ...

Eli Lilly and Company (NYSE:LLY) is included in our list of the 11 Best Rebound Stocks to Buy According to Hedge Funds. On August 8, 2025, JPMorgan maintained its ‘Overweight’ rating on Eli Lilly and ...

Eli Lilly is eligible for 100M in tax credits to expand its Pleasant Prairie facility, adding 750 jobs and boosting Wisconsin s biotech manufacturing sector.

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

The company says broad tariffs would raise costs, limit patient access and undermine domestic manufacturing. Eli Lilly is sounding a warning on proposed tariffs on pharmaceuticals, saying it would ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.